cas 2647-50-9, Flubromazepam | Articles data

Articles about 2647-50-9Total 7 be found

Structure-Activity Relationship Studies of Retro-1 Analogues against Shiga Toxin
High-throughput screening has shown that Retro-1 inhibits ricin and Shiga toxins by diminishing their intracellular trafficking via the retrograde route, from early endosomes to the Golgi apparatus. To improve the activity of Retro-1, a structure-activity relationship (SAR) study was undertaken and yielded an analogue with a roughly 70-fold better half-maximal effective concentration (EC50) against Shiga toxin cytotoxicity measured in a cell protein synthesis assay.
Abdelkafi, Hajer,Michau, Aurélien,Pons, Valérie,Ngadjeua, Flora,Clerget, Alexandra,Ait Ouarab, Lilia,Buisson, David-Alexandre,Montoir, David,Caramelle, Lucie,Gillet, Daniel,Barbier, Julien,Cintrat, Jean-Christophe
p. 8114 - 8133
(2020/09/21)

Synthesis of Flubromazepam Positional Isomers for Forensic Analysis
Designer benzodiazepines have recently appeared in many forensic cases as legal alternatives to federally scheduled drugs such as diazepam (Valium) and alprazolam (Xanax). Though current forensic instrumental techniques are often sufficient for identifying novel psychoactive substances, they may not readily differentiate between potential positional isomers. Additionally, characterization data for positional isomers of known designer benzodiazepines are widely nonexistent. In this study, flubromazepam, a recognized designer benzodiazepine since 2012, was targeted for synthesis and characterization due to its potential for federal scheduling and current legal status within the United States. A practical synthetic method was developed to prepare purified reference materials for each positional isomer of flubromazepam in which the positions of the bromine and fluorine substituents were varied. Possible isomers (9 of the 12) were successfully prepared and used for further analysis.
Allred, B. McKay,France, Stefan,Jones, Lonnie V.,Ligon, Evelyn S.,Nawyn, Jason,Reinhardt, Daniel V.
(2019/08/26)

Carboxamide GABAa ALPHA2 Modulators
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
-
Page/Page column 13

(2009/04/24)

CHEMICAL COMPOUNDS
The present invention relates to dihydrobenzodiazepine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such dihydrobenzodiazepine derivatives
-
Page/Page column 25-26

(2008/06/13)

Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.
-
Page/Page column 30

(2008/06/13)

ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS
Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.
-
Page/Page column 42

(2010/02/07)

Asymmetric Transformation. II. Racemization Reaction of 1,4-Benzodiazepinooxazole Derivative
Optically active crystals of 10-bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo-benzodiazepin-6(5H)-one were obtained by preferential crystallization; they were sometimes levorotatory and sometimes dextrorotatory.This phenomenon was pro
Okada, Yutaka,Takebayashi, Toyonori
p. 3787 - 3792
(2007/10/02)